KR20240135619A - 렌티바이러스-기반 비강 백신을 사용한 SARS-CoV-2 면역력 부스팅 방법 - Google Patents
렌티바이러스-기반 비강 백신을 사용한 SARS-CoV-2 면역력 부스팅 방법 Download PDFInfo
- Publication number
- KR20240135619A KR20240135619A KR1020247025586A KR20247025586A KR20240135619A KR 20240135619 A KR20240135619 A KR 20240135619A KR 1020247025586 A KR1020247025586 A KR 1020247025586A KR 20247025586 A KR20247025586 A KR 20247025586A KR 20240135619 A KR20240135619 A KR 20240135619A
- Authority
- KR
- South Korea
- Prior art keywords
- cov
- sars
- protein
- residue
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 188
- 229960005486 vaccine Drugs 0.000 title claims abstract description 66
- 230000036039 immunity Effects 0.000 title claims abstract description 39
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 79
- 239000000203 mixture Substances 0.000 claims abstract description 61
- 201000010099 disease Diseases 0.000 claims abstract description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 59
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims abstract description 55
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 49
- 230000003053 immunization Effects 0.000 claims abstract description 39
- 238000002649 immunization Methods 0.000 claims abstract description 39
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 37
- 241000700605 Viruses Species 0.000 claims abstract description 27
- 230000002163 immunogen Effects 0.000 claims abstract description 24
- 230000004044 response Effects 0.000 claims abstract description 24
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 22
- 229940023143 protein vaccine Drugs 0.000 claims abstract description 20
- 229940031626 subunit vaccine Drugs 0.000 claims abstract description 19
- 108010001267 Protein Subunits Proteins 0.000 claims abstract description 18
- 102000002067 Protein Subunits Human genes 0.000 claims abstract description 18
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 16
- 229940038694 mRNA-based vaccine Drugs 0.000 claims abstract description 14
- 108700021021 mRNA Vaccine Proteins 0.000 claims abstract description 12
- 229940126582 mRNA vaccine Drugs 0.000 claims abstract description 12
- 230000015654 memory Effects 0.000 claims abstract description 12
- 241000711573 Coronaviridae Species 0.000 claims abstract description 11
- 230000005923 long-lasting effect Effects 0.000 claims abstract description 7
- 230000024932 T cell mediated immunity Effects 0.000 claims abstract description 4
- 230000028996 humoral immune response Effects 0.000 claims abstract description 4
- 101710139375 Corneodesmosin Proteins 0.000 claims description 103
- 102100031673 Corneodesmosin Human genes 0.000 claims description 102
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 85
- 230000035772 mutation Effects 0.000 claims description 84
- 239000013598 vector Substances 0.000 claims description 77
- 239000002245 particle Substances 0.000 claims description 74
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 43
- 238000002255 vaccination Methods 0.000 claims description 42
- 235000018102 proteins Nutrition 0.000 claims description 34
- 208000015181 infectious disease Diseases 0.000 claims description 33
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 27
- 230000001681 protective effect Effects 0.000 claims description 25
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 22
- 230000009885 systemic effect Effects 0.000 claims description 21
- 210000002345 respiratory system Anatomy 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- 238000007918 intramuscular administration Methods 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 230000005867 T cell response Effects 0.000 claims description 12
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 11
- 102000004961 Furin Human genes 0.000 claims description 10
- 108090001126 Furin Proteins 0.000 claims description 10
- 108010074328 Interferon-gamma Proteins 0.000 claims description 10
- 210000003169 central nervous system Anatomy 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 9
- 102100037850 Interferon gamma Human genes 0.000 claims description 8
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 8
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 8
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 8
- 230000003362 replicative effect Effects 0.000 claims description 8
- 238000007920 subcutaneous administration Methods 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 7
- 102000000588 Interleukin-2 Human genes 0.000 claims description 7
- 229940096437 Protein S Drugs 0.000 claims description 7
- 101710198474 Spike protein Proteins 0.000 claims description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 7
- 229940024606 amino acid Drugs 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 238000010361 transduction Methods 0.000 claims description 7
- 230000026683 transduction Effects 0.000 claims description 7
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 7
- 230000000120 cytopathologic effect Effects 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 239000012636 effector Substances 0.000 claims description 6
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 3
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960003130 interferon gamma Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 229940124452 immunizing agent Drugs 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 230000003612 virological effect Effects 0.000 abstract description 28
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 abstract description 10
- 230000028993 immune response Effects 0.000 abstract description 10
- 238000009472 formulation Methods 0.000 abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 241000713666 Lentivirus Species 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 89
- 241000699670 Mus sp. Species 0.000 description 83
- 210000004072 lung Anatomy 0.000 description 78
- 241000494545 Cordyline virus 2 Species 0.000 description 70
- 241000699800 Cricetinae Species 0.000 description 66
- 108700022172 2019-nCoV Vaccine mRNA-1273 Proteins 0.000 description 35
- 229940026207 Moderna COVID-19 vaccine Drugs 0.000 description 35
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 32
- 229940027941 immunoglobulin g Drugs 0.000 description 27
- 230000003472 neutralizing effect Effects 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- 238000011529 RT qPCR Methods 0.000 description 19
- 239000000427 antigen Substances 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 239000012855 volatile organic compound Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 14
- 238000006386 neutralization reaction Methods 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 108091033319 polynucleotide Proteins 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 241001112090 Pseudovirus Species 0.000 description 12
- 108020000999 Viral RNA Proteins 0.000 description 12
- 230000002757 inflammatory effect Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 230000010076 replication Effects 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000029812 viral genome replication Effects 0.000 description 10
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000002055 immunohistochemical effect Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 6
- 108091027544 Subgenomic mRNA Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000011553 hamster model Methods 0.000 description 6
- 102000048657 human ACE2 Human genes 0.000 description 6
- 230000008348 humoral response Effects 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 210000003071 memory t lymphocyte Anatomy 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 4
- 229940022962 COVID-19 vaccine Drugs 0.000 description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
- 238000012313 Kruskal-Wallis test Methods 0.000 description 4
- 241000699673 Mesocricetus auratus Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000004727 humoral immunity Effects 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 210000001806 memory b lymphocyte Anatomy 0.000 description 4
- 238000011201 multiple comparisons test Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 102100033467 L-selectin Human genes 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000010212 intracellular staining Methods 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 3
- 229960001600 xylazine Drugs 0.000 description 3
- 102100022464 5'-nucleotidase Human genes 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101710114810 Glycoprotein Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 101000667982 Severe acute respiratory syndrome coronavirus 2 Envelope small membrane protein Proteins 0.000 description 2
- 101000667983 Severe acute respiratory syndrome coronavirus Envelope small membrane protein Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 101710167605 Spike glycoprotein Proteins 0.000 description 2
- 239000004138 Stearyl citrate Substances 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 229940031689 heterologous vaccine Drugs 0.000 description 2
- 238000007489 histopathology method Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 108010089520 pol Gene Products Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229940069575 rompun Drugs 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 210000001944 turbinate Anatomy 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 229940125579 COVID-19 vaccine candidate Drugs 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 241001217856 Chimpanzee adenovirus Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000314928 Cordyline virus 1 Species 0.000 description 1
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 101001112318 Dictyostelium discoideum Nucleoside diphosphate kinase, cytosolic Proteins 0.000 description 1
- 231100000491 EC50 Toxicity 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101001131829 Homo sapiens P protein Proteins 0.000 description 1
- 101001128731 Homo sapiens Putative nucleoside diphosphate kinase Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000942626 Homo sapiens UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000029464 Pulmonary infiltrates Diseases 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108091006197 SARS-CoV-2 Nucleocapsid Protein Proteins 0.000 description 1
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 101100316897 Severe acute respiratory syndrome coronavirus 2 E gene Proteins 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 1
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000047119 human OCA2 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000003312 immunocapture Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 230000018711 interleukin-13 production Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 230000022023 interleukin-5 production Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012768 mass vaccination Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 108700001624 vesicular stomatitis virus G Proteins 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000007485 viral shedding Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000010153 Šidák test Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB2022/000035 | 2022-01-17 | ||
| PCT/IB2022/000035 WO2023135439A1 (en) | 2022-01-17 | 2022-01-17 | Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine |
| PCT/EP2023/051025 WO2023135333A1 (en) | 2022-01-17 | 2023-01-17 | Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240135619A true KR20240135619A (ko) | 2024-09-11 |
Family
ID=80787107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247025586A Pending KR20240135619A (ko) | 2022-01-17 | 2023-01-17 | 렌티바이러스-기반 비강 백신을 사용한 SARS-CoV-2 면역력 부스팅 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250090655A1 (https=) |
| EP (1) | EP4466015A1 (https=) |
| JP (1) | JP2025504431A (https=) |
| KR (1) | KR20240135619A (https=) |
| CN (1) | CN118829444A (https=) |
| AU (1) | AU2023207825A1 (https=) |
| CA (1) | CA3242669A1 (https=) |
| TW (1) | TW202337492A (https=) |
| WO (2) | WO2023135439A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| WO2024050483A1 (en) * | 2022-08-31 | 2024-03-07 | Modernatx, Inc. | Variant strain-based coronavirus vaccines and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023517286A (ja) * | 2020-03-13 | 2023-04-25 | オックスフォード ユニヴァーシティ イノヴェーション リミテッド | 免疫応答を誘導するための組成物及び方法 |
| CN117120085A (zh) * | 2020-07-15 | 2023-11-24 | 巴斯德研究所 | Sars-cov-2免疫原性组合物、疫苗和方法 |
| CA3185952A1 (en) * | 2020-07-15 | 2022-01-20 | Pierre Charneau | Sars-cov-2 immunogenic compositions, vaccines, and methods |
| WO2022167831A1 (en) * | 2021-02-02 | 2022-08-11 | Institut Pasteur | Sars-cov-2 immunogenic compositions, vaccines, and methods |
-
2022
- 2022-01-17 WO PCT/IB2022/000035 patent/WO2023135439A1/en not_active Ceased
-
2023
- 2023-01-17 JP JP2024542183A patent/JP2025504431A/ja active Pending
- 2023-01-17 WO PCT/EP2023/051025 patent/WO2023135333A1/en not_active Ceased
- 2023-01-17 EP EP23701288.5A patent/EP4466015A1/en active Pending
- 2023-01-17 KR KR1020247025586A patent/KR20240135619A/ko active Pending
- 2023-01-17 TW TW112102010A patent/TW202337492A/zh unknown
- 2023-01-17 CN CN202380017293.1A patent/CN118829444A/zh active Pending
- 2023-01-17 CA CA3242669A patent/CA3242669A1/en active Pending
- 2023-01-17 AU AU2023207825A patent/AU2023207825A1/en active Pending
- 2023-01-17 US US18/726,286 patent/US20250090655A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023207825A1 (en) | 2024-08-08 |
| EP4466015A1 (en) | 2024-11-27 |
| CN118829444A (zh) | 2024-10-22 |
| WO2023135439A1 (en) | 2023-07-20 |
| US20250090655A1 (en) | 2025-03-20 |
| AU2023207825A9 (en) | 2024-08-15 |
| JP2025504431A (ja) | 2025-02-12 |
| CA3242669A1 (en) | 2023-07-20 |
| TW202337492A (zh) | 2023-10-01 |
| WO2023135333A1 (en) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230021583A1 (en) | Measles-vectored covid-19 immunogenic compositions and vaccines | |
| Law et al. | SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1 | |
| Gallinaro et al. | Integrase defective lentiviral vector as a vaccine platform for delivering influenza antigens | |
| US20240226291A9 (en) | Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus | |
| Yao et al. | Virus-like particle and DNA-based candidate AIDS vaccines | |
| US20230256084A1 (en) | Sars-cov-2 immunogenic compositions, vaccines, and methods | |
| Pérez et al. | Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection | |
| JP2023526073A (ja) | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン | |
| AU2021226567A1 (en) | Vaccines against coronavirus and methods of use | |
| Vassilieva et al. | Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant | |
| KR20240135619A (ko) | 렌티바이러스-기반 비강 백신을 사용한 SARS-CoV-2 면역력 부스팅 방법 | |
| Moliva et al. | Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates | |
| Moriya et al. | Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies | |
| Ku et al. | Intranasal vaccination with a lentiviral vector strongly protects against SARS-CoV-2 in mouse and golden hamster preclinical models | |
| WO2022167831A1 (en) | Sars-cov-2 immunogenic compositions, vaccines, and methods | |
| WO2022236301A1 (en) | Vaccines against coronavirus and methods of use | |
| US20250325657A1 (en) | Modified vaccinia ankara (mva) vaccine | |
| WO2013126469A1 (en) | Chimeric dna vaccine compositions and methods of use | |
| Edwards | Immunogenicity and protection mediated by next-generation EBV gH/gL vaccines in non-human primate and humanized mouse models of infection | |
| García-Arriaza et al. | MVA-based vaccine against COVID-19 expressing SARS-CoV-2 antigens | |
| Castaño Monsalve et al. | A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice | |
| CN117479953A (zh) | 针对冠状病毒的疫苗及其使用方法 | |
| Reed et al. | Design and immunogenicity of a Pan-SARS-CoV-2 synthetic DNA vaccine | |
| Lucy Kuo et al. | A Novel SARS-CoV-2 Multitope Protein/Peptide Vaccine Candidate is Highly | |
| Center et al. | Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20240729 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application |